![]() |
市場調查報告書
商品編碼
1497628
細胞治療市場:按支架、按應用分類 - 2024-2030 年全球預測Acellular Therapy Market by Scaffold (Cell Laden Hydrogel, Extracellular Matrix (ECM), Fused Deposition Modeling (FDM)), Application (Cardiology, Gastroenterology, Hepatology) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年細胞治療市場規模為110.7億美元,預計2024年將達到124.9億美元,2030年將達到266.5億美元,複合年成長率為13.37%。
細胞療法代表再生醫學的一個分支,利用細胞成分來修復和再生組織和器官。這些成分包括多種生物分子,如蛋白質、胜肽、生長因子、細胞外基質(ECM)成分和合成的生物活性化合物,但不包括活細胞。該治療方法利用這些細胞材料的領導潛力來刺激身體的內部修復機制並為組織再生提供支架。 KEYWORD 市場成長受到慢性病盛行率增加、治療技術進步以及再生醫學研究投資增加等因素的影響。此外,政府積極支持再生醫學的努力也正在加速細胞療法的交付。然而,療法開發的高成本、嚴格的監管要求以及製造流程的複雜性影響了細胞療法的開發。細胞治療市場的潛在機會包括開拓具有增強生物相容性和生物活性的生醫材料、與技術公司合作開發先進製造技術以及開拓新興國家開拓的市場。
主要市場統計 | |
---|---|
基準年[2023] | 110.7億美元 |
預測年份 [2024] | 124.9億美元 |
預測年份 [2030] | 266.5億美元 |
複合年成長率(%) | 13.37% |
區域洞察
在美國,特別是美國,細胞療法已廣泛應用於多種臨床應用,包括創傷治療、整形外科治療以及最近的整容手術。 Acela 療法在美洲的生產非常複雜,嚴格的 FDA 法規確保了最高的品質和安全標準。在亞太地區,日本、韓國、中國和印度等國家正成為細胞治療的重要市場。在這些國家,不斷成長的糖尿病人口增加了這些治療方法在慢性傷口和糖尿病潰瘍治療中的使用。此外,經濟成長和醫療保健投資使亞太地區成為新興的醫療旅遊中心,直接影響細胞治療藥物等先進治療方法的使用。中國和韓國特別投資擴大產能,而日本則以其再生醫學創新而聞名。歐洲擁有成熟的細胞治療市場,擁有用於傷口護理、組織再生和外科應用的先進產品。許多大公司已經進入這個領域並正在推動技術創新。中東和非洲部分地區也認知到了蜂窩產品的潛力,但由於廣大地區的經濟和醫療保健系統不同,其採用情況並不均衡。歐洲國家擁有符合 EMA 指南的強大生產框架,確保高品質生產。德國、英國、法國等生物技術中心擁有強大的生產能力。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在細胞治療市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對細胞治療市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在細胞治療市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[195 Pages Report] The Acellular Therapy Market size was estimated at USD 11.07 billion in 2023 and expected to reach USD 12.49 billion in 2024, at a CAGR 13.37% to reach USD 26.65 billion by 2030.
Acellular therapy represents a branch of regenerative medicine that utilizes acellular components with the goal of repairing or regenerating tissues and organs. These components can include various biomolecules such as proteins, peptides, growth factors, extracellular matrix (ECM) components, and synthetic bioactive compounds but lack any living cells. This form of therapy harnesses the instructive potential of these acellular materials to stimulate the body's intrinsic repair mechanisms or to provide a scaffold for tissue regeneration. The growth of the acellular therapy market is influenced by factors such as the increasing prevalence of chronic diseases, advancements in treatment technology, and growing investments in regenerative medicine research. Further, favorable government initiatives to support regenerative medicine have also accelerated the provision of acellular therapy. However, the high cost of therapy development, stringent regulatory requirements, and the complexity of the manufacturing process impact the acellular therapy development. Potential opportunities within the acellular therapy market include the development of biomaterials with enhanced biocompatibility and bioactivity, collaboration with technology companies for advanced manufacturing techniques, and exploring untapped markets in developing countries.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 11.07 billion |
Estimated Year [2024] | USD 12.49 billion |
Forecast Year [2030] | USD 26.65 billion |
CAGR (%) | 13.37% |
Regional Insights
The Americas, particularly the United States, have witnessed widespread adoption of acellular therapy across multiple clinical applications, including wound healing, orthopedic treatments, and, increasingly, cosmetic procedures. The production of acellular therapies in the Americas is highly sophisticated, with stringent FDA regulations ensuring the highest quality and safety standards. In the APAC region, countries such as Japan, South Korea, China, and India are emerging as significant markets for acellular therapy. These countries are seeing increasing use of these therapies in managing chronic wounds and diabetic ulcers due to a growing diabetic population. Further, growing economies and healthcare investments have seen the APAC become a burgeoning medical tourism hub, directly impacting the use of advanced therapies such as acellular therapeutics. China and South Korea are particularly invested in scaling up production capacity, and Japan is known for its innovation in regenerative medicine. Europe has a well-established acellular therapy market, with advanced products used in wound care, tissue regeneration, and surgical applications. The presence of a number of leading companies here drives innovation in the sector. The Middle East and parts of Africa are also recognizing the potential for acellular products; however, their adoption is varied due to differing economic and healthcare systems within the vast region. European countries have robust production frameworks governed by EMA guidelines, which ensure high-quality production. Biotechnology hubs in countries including Germany, the UK, and France have strong production capabilities.
Market Insights
The market dynamics represent an ever-changing landscape of the Acellular Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acellular Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acellular Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
Humacyte, Inc. unveiled promising results from its pivotal V005 Phase 2/3 study concerning the application of the Human Acellular Vessel (HAV) for emergency vascular trauma repair. This single-arm clinical trial demonstrated that HAV displayed a superior performance, with higher patency rates and notably fewer occurrences of amputation and infection when juxtaposed with historical data on synthetic vascular grafts. [Published On: 2023-09-12]
FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes
The U.S. Food and Drug Administration (FDA) has greenlit Lantidra (donislecel-jujn), a pioneering cellular therapy treatment for adults with type 1 diabetes who consistently struggle to reach their target HbA1c levels due to recurrent severe hypoglycemia, despite undergoing rigorous diabetes management and education. Engineered as the first allogeneic pancreatic islet cell therapy sanctioned by the FDA, Lantidra facilitates insulin regulation through the delivery of allogeneic islet beta cells. [Published On: 2023-06-29]
Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
Humacyte, Inc. a pioneering clinical-stage biotech firm specializing in the development of universally implantable bioengineered human tissues, has initiated a humanitarian project to distribute its revolutionary Human Acellular Vessels (HAVs) to several Ukrainian hospitals for critical vascular repair treatment in both civilians and military personnel suffering from vascular injuries. The inaugural batch of HAVs, designed as engineered, off-the-shelf vessels for a variety of vascular treatments, has embarked for Ukraine, targeting six medical facilities across cities including Kyiv and Kharkiv. [Published On: 2022-05-09]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acellular Therapy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.
Market Segmentation & Coverage